KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Leerink Partnrs lowered their Q3 2024 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, February 13th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will post earnings per share of ($0.69) for the quarter, down from […]
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) $KALV KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro.
CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) $KALV KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an.